STOCK TITAN

Abeona Therapeutics (ABEO) CCO sells 12,606 shares, retains 290,623

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Abeona Therapeutics Inc. Chief Commercial Officer Madhav Vasanthavada reported an open-market sale of 12,606 shares of common stock at a weighted average price of $6.9637 per share. After this transaction, he directly holds 290,623 shares, indicating that only a small portion of his position was sold.

Positive

  • None.

Negative

  • None.
Insider Vasanthavada Madhav
Role Chief Commercial Officer
Sold 12,606 shs ($88K)
Type Security Shares Price Value
Sale Common Stock 12,606 $6.9637 $88K
Holdings After Transaction: Common Stock — 290,623 shares (Direct, null)
Footnotes (1)
  1. Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Shares sold 12,606 shares Open-market sale of common stock on reported transaction date
Weighted average sale price $6.9637 per share Average price across multiple trades in the reported sale
Post-transaction holdings 290,623 shares Common stock held directly after the sale
Trade price range $6.86–$7.04 per share Range of individual trade prices within the reported transaction
Net shares sold 12,606 shares Net change in position from this Form 4, per summary data
open-market sale financial
"reported an open-market sale of 12,606 shares of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
non-derivative financial
"The filing reports a non-derivative open-market sale of common stock"
Form 4 regulatory
"What insider transaction did Abeona Therapeutics (ABEO) disclose in this Form 4?"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
transaction code "S" regulatory
"coded as an “S” transaction. This indicates shares previously owned outright"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did Abeona Therapeutics (ABEO) disclose in this Form 4?

Abeona Therapeutics reported that Chief Commercial Officer Madhav Vasanthavada executed an open-market sale of 12,606 shares of common stock. This sale was reported as a non-derivative transaction involving directly held shares.

At what price were the Abeona Therapeutics (ABEO) shares sold in the Form 4?

The shares were sold at a weighted average price of $6.9637 per share. A footnote explains the trades occurred in multiple transactions between $6.86 and $7.04 inclusive, reflecting typical market execution.

How many Abeona Therapeutics (ABEO) shares does the insider hold after the sale?

Following the reported sale, Chief Commercial Officer Madhav Vasanthavada directly holds 290,623 shares of Abeona Therapeutics common stock. This shows the transaction affected a relatively small portion of his overall reported holdings.

What type of transaction is reported in this Abeona Therapeutics (ABEO) Form 4?

The filing reports a non-derivative open-market sale of common stock, coded as an “S” transaction. This indicates shares previously owned outright were sold rather than options or other derivative securities being exercised.

Does the Abeona Therapeutics (ABEO) Form 4 mention how the sale was executed?

Yes. A footnote states the reported price is a weighted average because the shares were sold in multiple trades. These trades occurred at prices ranging from $6.86 to $7.04 per share, all on the same transaction date.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Vasanthavada Madhav

(Last)(First)(Middle)
6555 CARNEGIE AVE., 4TH FLOOR

(Street)
CLEVELAND OHIO 44103

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/09/2026S(1)12,606D$6.9637(2)290,623D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents shares withheld to satisfy tax withholding obligations upon vesting of restricted stock awards.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.86 to $7.04 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ Joseph Vazzano, Attorney-in-Fact07/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)